# OrphanCure Full Pipeline Report: repodb_074e03e7fac6728e

- Drug: Irinotecan
- Disease: signet ring adenocarcinoma of the rectum
- Mode: no_verifier
- Status: completed
- Final assessment: Unlikely

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Unlikely",
      "confidence": "Low",
      "summary": "No literature was retrieved to support or refute the repurposing of Irinotecan for rectal signet ring cell adenocarcinoma. Therefore, based on the current data, this repurposing is unlikely.",
      "evidence_counts": {
        "total_papers": 0,
        "supporting": 0,
        "contradicting": 0,
        "inconclusive": 0
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose IRINOTECAN for rectal signet ring cell adenocarcinoma",
      "drug": {
        "id": "CHEMBL481",
        "name": "IRINOTECAN",
        "aliases": [
          "CPT-11",
          "Camptosar",
          "Irinotecan hydrochloride",
          "Onivyde",
          "Topoisomerase 1 inhibitor"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0004336",
        "name": "rectal signet ring cell adenocarcinoma",
        "aliases": [
          "Rectal signet ring carcinoma",
          "Adenocarcinoma, signet ring cell, of rectum",
          "Signet ring cell adenocarcinoma of the rectum",
          "Rectal SRC",
          "Signet ring cell carcinoma of rectum"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 0,
      "polarity": {
        "supports": 0,
        "contradicts": 0,
        "inconclusive": 0
      },
      "support_ratio": "No papers retrieved",
      "queries_used": 10,
      "top_papers": []
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Low",
      "dimensions": {
        "mechanistic_strength": "Low",
        "literature_strength": "Low",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.388,
        "decision": "rerun",
        "dimensions": {
          "completeness": {
            "score": 0.8,
            "reason": "4/5 sections present"
          },
          "evidence_support": {
            "score": 0.0,
            "reason": "No claims generated"
          },
          "citation_validity": {
            "score": 0.0,
            "reason": "0 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/0 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 0.0,
            "reason": "0/0 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "evidence_support",
          "citation_validity",
          "mechanistic_specificity",
          "contradiction_handling",
          "traceability"
        ],
        "rerun_targets": [
          "LiteratureAgent",
          "MechanismAgent",
          "SynthesisCriticAgent"
        ]
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Lack of supporting evidence.",
        "Potential for off-target effects if mechanism is not well-defined for this specific subtype."
      ],
      "limitations": [
        "The absence of retrieved literature severely limits the ability to assess the hypothesis.",
        "The analysis is based solely on the lack of provided data, not on any positive or negative findings."
      ],
      "missing_data": [
        "Studies investigating Irinotecan's efficacy in rectal signet ring cell adenocarcinoma.",
        "Preclinical data on Irinotecan's activity against signet ring cell adenocarcinoma.",
        "Clinical trial data for Irinotecan in this specific indication."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Conduct a thorough literature search using broader keywords and databases.",
        "Investigate the known mechanisms of Irinotecan and signet ring cell adenocarcinoma to identify potential molecular links.",
        "Explore preclinical studies of Irinotecan in relevant cell lines or animal models of rectal signet ring cell adenocarcinoma."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 0,
      "claims": []
    },
    "11_provenance_appendix": {
      "total_entries": 0,
      "entries": []
    }
  },
  "metadata": {
    "run_id": "c45ea352725b",
    "created_at": "2026-06-03T11:57:27.736408+00:00",
    "drug": "IRINOTECAN",
    "disease": "rectal signet ring cell adenocarcinoma",
    "total_claims": 0,
    "quality_score": 0.3875,
    "reruns": 0
  }
}
```
